Literature DB >> 12128119

Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging.

Mark Rijpkema1, Johannes H A M Kaanders, Frank B M Joosten, Albert J van der Kogel, Arend Heerschap.   

Abstract

PURPOSE: For head-and-neck tumors, breathing a hyperoxic hypercapnic gas mixture and administration of nicotinamide has been shown to result in a significantly improved tumor response to accelerated radiotherapy (ARCON, Accelerated Radiotherapy with CarbOgen and Nicotinamide). This may be caused by improved tumor oxygenation, possibly mediated by vascular effects. In this study, both blood oxygenation and vascular effects of breathing a hyperoxic hypercapnic gas mixture (98% O2 + 2% CO2) were assessed by magnetic resonance imaging (MRI) in patients with head-and-neck tumors. METHODS AND MATERIALS: Tumor vascularity and oxygenation were investigated by dynamic gadolinium contrast-enhanced MRI and blood oxygen level dependent (BOLD) MRI, respectively. Eleven patients with primary head-and-neck tumors were each measured twice; with and without breathing the hyperoxic hypercapnic gas mixture.
RESULTS: BOLD MR imaging revealed a significant increase of the MRI time constant of transverse magnetization decay (T2*) in the tumor during hypercapnic hyperoxygenation, which correlates to a decrease of the deoxyhemoglobin concentration. No changes in overall tumor vascularity were observed, as measured by the gadolinium contrast uptake rate in the tumor.
CONCLUSION: Breathing a hyperoxic hypercapnic gas mixture improves tumor blood oxygenation in patients with head-and-neck tumors, which may contribute to the success of the ARCON therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128119     DOI: 10.1016/s0360-3016(02)02825-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  39 in total

1.  Head and neck cancer: how imaging predicts treatment outcome.

Authors:  Robert Hermans
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Authors:  Simon P Robinson; Tammy L Kalber; Franklyn A Howe; Dominick J O McIntyre; John R Griffiths; David C Blakey; Lynsey Whittaker; Anderson J Ryan; John C Waterton
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Relationship between tumour growth rate and carbogen-based functional MRI for a chemically induced HCC in mice.

Authors:  C D Thomas; E Chenu; C Walczak; M-J Plessis; F Perin; A Volk
Journal:  MAGMA       Date:  2004-12-20       Impact factor: 2.310

Review 4.  The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Authors:  Kee H Wong; Rafal Panek; Shreerang A Bhide; Christopher M Nutting; Kevin J Harrington; Katie L Newbold
Journal:  Br J Radiol       Date:  2017-03       Impact factor: 3.039

5.  PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.

Authors:  Svetlana Balyasnikova; Johan Löfgren; Robin de Nijs; Yanna Zamogilnaya; Liselotte Højgaard; Barbara M Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

6.  Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.

Authors:  Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 7.  Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.

Authors:  James P B O'Connor; Simon P Robinson; John C Waterton
Journal:  Br J Radiol       Date:  2019-01-24       Impact factor: 3.039

8.  Application of an exogenous hyperoxic contrast agent in MR mammography: initial results.

Authors:  Dorothee R Fischer; Jürgen R Reichenbach; Alexander Rauscher; Jan Sedlacik; Werner A Kaiser
Journal:  Eur Radiol       Date:  2004-09-22       Impact factor: 5.315

Review 9.  Defining the target for radiotherapy of head and neck cancer.

Authors:  S Nuyts
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 10.  Multimodality imaging of head and neck cancer.

Authors:  A D King
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.